Advances in the anti-tumor potential of hederagenin and its analogs

• Published in: European journal of pharmacology 2023-11, Vol.959, p.176073-176073, Article 176073
• Main Authors: Xie, Wenbin, Fang, Xianhe, li, Haixia, Lu, Xilang, Yang, Dong, Han, Song, Bi, Yi
• Format: Article
• Language: English
• Subjects: Anti-tumor; Derivatives; Hederagenin; Natural product; Structure–activity relationship
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2023.176073

Hederagenin is a pentacyclic triterpenoid that is widely distributed as the main pharmaceutical ingredient in various medicinal plants. Similarly as other pentacyclic triterpenoids, hederagenin has various pharmacological effects such as anti-tumor, anti-inflammatory, anti-depressant, and anti-viral activities. In particular, the anti-tumor activity of hederagenin indicates its potential for development into highly effective chemotherapeutic agents. Studies revealed that hederagenin effectively suppresses the growth of various tumor cell lines in vitro and interacts with several molecular targets that play essential roles in various cellular signaling pathways. The compound suppresses transformation, inhibits proliferation, and induces apoptosis in tumor cells. In this review, we highlight research progress on the source, pharmacokinetics, pharmacological activity, and mechanism of action of hederagenin and the anti-tumor activity of its analogs by integrating and analyzing relevant domestic and international studies and providing a basis for their further development and application.